Zhemal Rakhmanova retweetledi

In our new research doi.org/10.3390/cancer… we found that a low level of CD68+ and CD163+ cells had a negative effect on PFS in patients with r/r cHL, while a low level of M2 (CD163/c-maf+) macrophages improved the prognosis of patients during #nivolumab therapy.


English





























